The firm now has a $22.00 target price on the biopharmaceutical company's stock.
A number of other research firms also recently issued reports on CARA.
Shares of Cara Therapeutics Inc (NASDAQ:CARA) inclined 3.79% to $13.95.
The difference of 52 week low value as well as 52 week high value and the current price of the stock suggests the next move of the shares. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has "Buy" rating by Canaccord Genuity on Friday, June 30. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The short sellers will then buy the stock back at a much lower price and replace the borrowed shares, pocketing the difference.More news: The Incredibles 2 begins where the original ended
Shares of Cara Therapeutics (CARA) opened at 13.95 on Wednesday. ViewRay, Inc. tumbled -36.64% from its high of $10.39 to a $382.43 million market value through last close. Cara Therapeutics has a 12 month low of $4.75 and a 12 month high of $28.50. The firm's 50 day moving average price is $18.44 and its 200-day moving average price is $15.55.
Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.11 million. The firm's revenue was up 12900.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.39) EPS. Cara Therapeutics, Inc. (CARA) received interesting focus from Active Investors and it has been trading on front line as comparing to it past average volume. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of USA and global trademark & copyright legislation. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and worldwide copyright and trademark law. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/07/14/cara-therapeutics-nasdaqcara-buy-rating-reaffirmed-at-janney-montgomery-scott-updated.html.
In related news, Director Dean Slagel sold 250,000 shares of the stock in a transaction dated Thursday, June 29th. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. The sale was disclosed in a filing with the SEC, which can be accessed through this link. RHO Capital Partners Inc. now owns 3,568,057 shares of the biopharmaceutical company's stock valued at $65,617,000 after buying an additional 500,000 shares in the last quarter. Hedge funds and other institutional investors own 52.91% of the company's stock. UBS Group AG increased its stake in Cara Therapeutics by 16.9% in the first quarter. Finally, State Street Corp boosted its stake in shares of Cara Therapeutics by 7.1% in the fourth quarter. Over the last week of the month, it was -7.37%, -23.27% over the last quarter, and 28.10% for the past six months. Cambridge Investment Research Advisors Inc. increased its stake in Cara Therapeutics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 229,626 shares of the biopharmaceutical company's stock worth $2,133,000 after buying an additional 62,518 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Cara Therapeutics during the first quarter worth $252,000.
Frédérique Menzaghi, Ph.D., the VP of R&D at Cara Therapeutics, reported that they are delighted to state that plasma levels of CR845 achieved with oral tablets exceeded or equaled plasma levels formerly linked with clinically efficacious I.V. The doses of CR845 in hemodialysis subjects with moderate-to-severe CKD-linked pruritus.